The changing microbiologic epidemiology of community-acquired pneumonia (Q38160635)

30 August 2017

The changing microbiologic epidemiology of community-acquired pneumonia (English)

1 reference

30 August 2017

0 references

language of work or name

English

0 references

publication date

1 November 2013

1 reference

30 August 2017

Postgraduate Medicine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24200759%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24200759%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24200759%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

31-42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24200759%20AND%20SRC:MED&resulttype=core&format=json

Burden of community-acquired pneumonia in North American adults

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Clinical and economic burden of community-acquired pneumonia among adults in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Acute pneumonia and the cardiovascular system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Long-term mortality after pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Acute myocardial infarction in hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Clinical and economic burden of community-acquired pneumonia among adults in the Czech Republic, Hungary, Poland and Slovakia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Additional risk factors for infection by multidrug-resistant pathogens in healthcare-associated infection: a large cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Incidence of childhood pneumonia and serotype and sequence-type distribution in Streptococcus pneumoniae isolates in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Community-Acquired Pneumonia: An Unfinished Battle

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

What is the role of antimicrobial stewardship in improving outcomes of patients with CAP?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Infectious disease hospitalizations in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Global changes in the epidemiology of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Prevalence of methicillin-resistant staphylococcus aureus as an etiology of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Bacterial coinfection in influenza: a grand rounds review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Methicillin-resistant Staphylococcus aureus in community-acquired and health care-associated pneumonia: incidence, diagnosis, and treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

The relationship between pneumococcal serotypes and antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Increase in prevalence of Streptococcus pneumoniae serotype 6C at Eight Children's Hospitals in the United States from 1993 to 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Novel pneumococcal serotypes 6C and 6D: anomaly or harbinger.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Is methicillin-resistant Staphylococcus aureus pneumonia epidemiology and sensitivity changing?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Staphylococcus aureus pneumonia in children in the era of community-acquired methicillin-resistance at Texas Children's Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Radiological findings of community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus pediatric pneumonia in Hawaii

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Methicillin-resistant Staphylococcus aureus disease in three communities

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Fatal necrotizing pneumonia due to a Panton-Valentine leukocidin positive community-associated methicillin-sensitive Staphylococcus aureus and Influenza co-infection: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Staphylococcus aureus pneumonia: a "superbug" infection in community and hospital settings

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Healthcare-associated pneumonia: a US disease or relevant to the Asia Pacific, too?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Guidelines for the management of adult lower respiratory tract infections--full version

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Health care-associated pneumonia and community-acquired pneumonia: a single-center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Initial treatment failure in non-ICU community-acquired pneumonia: risk factors and association with length of stay, total hospital charges, and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Community-acquired methicillin-resistant Staphylococcus aureus pneumonia: a clinical audit

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

The association between pneumococcal pneumonia and acute cardiac events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.11.2710

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.11.2710

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24200759%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference